1 Biotech + 2 Cancer Drugs = 100% Pop

Shares of the small-cap biotech Clovis Oncology soared after presenting data on two drugs -- one for lung cancer and another that's tied to the same genetically defective BRCA function that made Angelina Jolie decide to get a double mastectomy.

That would be rucaparib, the PARP inhibitor Clovis licensed from Big Pharma Pfizer. The class of drugs had a big showing at the ASCO conference and caused a number of big pops and drops today. 

The unexpectedly strong data for early stage lung cancer drug CO-1686 surprised investors.  As potentially the first treatment for those with the T790M mutation, this could be an incredibly important product.

In this video, health-care analyst David Williamson discusses what these events mean for investors in Clovis and also for its competitors.

Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare" lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 04, 2013, at 7:21 AM, EllenBrandtPhD wrote:

    David, Thanks for the story.

    But potentially big financial news for PFE - aside from Zoetis on the 19th - came out very quietly early this morning in some NJ and PA media outlets, but nowhere else yet.

    That's the beginning of the trial in a multibillion - with a B - lawsuit PFE is pursuing against Teva and its Indian partner, Sun, for patent infringement.

    According to early stories, although these cases are difficult to pursue, PFE has a pretty good chance of either winning outright or being gifted with a hefty settlement.

    In any case, Fool, Reuters, Bloomie's and the others need to pick up on this story this morning. PFE finally has some upwards momentum again, and this could clinch the positive sentiment returning.

Add your comment.

DocumentId: 2469225, ~/Articles/ArticleHandler.aspx, 4/20/2014 3:50:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement